UCB SA (UCBJF)
USD 195.88
(0.0%)
USD 195.88
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.87 Billion EUR | 9.1% |
| 2022 | 2.63 Billion EUR | 27.56% |
| 2021 | 2.06 Billion EUR | -10.71% |
| 2020 | 2.31 Billion EUR | 137.54% |
| 2019 | 975 Million EUR | -27.78% |
| 2018 | 1.35 Billion EUR | -11.99% |
| 2017 | 1.53 Billion EUR | -2.54% |
| 2016 | 1.57 Billion EUR | -0.69% |
| 2015 | 1.58 Billion EUR | -9.27% |
| 2014 | 1.74 Billion EUR | -13.81% |
| 2013 | 2.02 Billion EUR | 7.25% |
| 2012 | 1.89 Billion EUR | 6.66% |
| 2011 | 1.77 Billion EUR | 0.8% |
| 2010 | 1.75 Billion EUR | 4.83% |
| 2009 | 1.67 Billion EUR | -15.98% |
| 2008 | 1.99 Billion EUR | 4.72% |
| 2007 | 1.9 Billion EUR | -37.49% |
| 2006 | 3.04 Billion EUR | 197.75% |
| 2005 | 1.02 Billion EUR | 314.55% |
| 2004 | 247.01 Million EUR | -19.74% |
| 2003 | 307.78 Million EUR | 152.94% |
| 2002 | 121.68 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.84 Billion EUR | 0.0% |
| 2024 Q1 | 2.98 Billion EUR | -1.11% |
| 2023 Q2 | 2.62 Billion EUR | 0.0% |
| 2023 FY | 2.87 Billion EUR | 9.1% |
| 2023 Q3 | 2.99 Billion EUR | 14.31% |
| 2023 Q4 | 2.87 Billion EUR | -3.94% |
| 2023 Q1 | 2.62 Billion EUR | -0.64% |
| 2022 Q2 | 2.88 Billion EUR | 0.0% |
| 2022 Q4 | 2.63 Billion EUR | 0.0% |
| 2022 FY | 2.63 Billion EUR | 27.56% |
| 2022 Q1 | 2.88 Billion EUR | 39.7% |
| 2022 Q3 | 2.63 Billion EUR | -8.69% |
| 2021 Q1 | 2.01 Billion EUR | -13.04% |
| 2021 Q2 | 2.01 Billion EUR | 0.0% |
| 2021 Q4 | 2.06 Billion EUR | 0.0% |
| 2021 Q3 | 2.06 Billion EUR | 2.68% |
| 2021 FY | 2.06 Billion EUR | -10.71% |
| 2020 Q4 | 2.31 Billion EUR | 0.0% |
| 2020 Q1 | 2.46 Billion EUR | 152.72% |
| 2020 Q3 | 2.31 Billion EUR | -6.01% |
| 2020 FY | 2.31 Billion EUR | 137.54% |
| 2020 Q2 | 2.46 Billion EUR | 0.0% |
| 2019 Q3 | 975 Million EUR | -2.69% |
| 2019 FY | 975 Million EUR | -27.78% |
| 2019 Q1 | 1 Billion EUR | -25.78% |
| 2019 Q2 | 1 Billion EUR | 0.0% |
| 2019 Q4 | 975 Million EUR | 0.0% |
| 2018 Q3 | 1.35 Billion EUR | -6.83% |
| 2018 Q1 | 1.44 Billion EUR | -5.54% |
| 2018 FY | 1.35 Billion EUR | -11.99% |
| 2018 Q4 | 1.35 Billion EUR | 0.0% |
| 2018 Q2 | 1.44 Billion EUR | 0.0% |
| 2017 Q2 | 1.55 Billion EUR | 0.0% |
| 2017 Q3 | 1.53 Billion EUR | -1.03% |
| 2017 Q4 | 1.53 Billion EUR | 0.0% |
| 2017 FY | 1.53 Billion EUR | -2.54% |
| 2017 Q1 | 1.55 Billion EUR | -1.52% |
| 2016 Q1 | 1.6 Billion EUR | 0.95% |
| 2016 FY | 1.57 Billion EUR | -0.69% |
| 2016 Q4 | 1.57 Billion EUR | -1.38% |
| 2016 Q3 | 1.59 Billion EUR | -0.25% |
| 2016 Q2 | 1.6 Billion EUR | 0.0% |
| 2015 Q1 | 2.08 Billion EUR | 19.58% |
| 2015 Q3 | 1.65 Billion EUR | -20.68% |
| 2015 FY | 1.58 Billion EUR | -9.27% |
| 2015 Q4 | 1.58 Billion EUR | -4.35% |
| 2015 Q2 | 2.08 Billion EUR | 0.0% |
| 2014 Q2 | 1.65 Billion EUR | 0.0% |
| 2014 Q1 | 1.65 Billion EUR | -18.4% |
| 2014 FY | 1.74 Billion EUR | -13.81% |
| 2014 Q4 | 1.74 Billion EUR | 0.0% |
| 2014 Q3 | 1.74 Billion EUR | 5.62% |
| 2013 Q2 | 2.23 Billion EUR | 0.0% |
| 2013 Q1 | 2.23 Billion EUR | 18.2% |
| 2013 Q4 | 2.02 Billion EUR | 0.0% |
| 2013 FY | 2.02 Billion EUR | 7.25% |
| 2013 Q3 | 2.02 Billion EUR | -9.27% |
| 2012 FY | 1.89 Billion EUR | 6.66% |
| 2012 Q2 | 1.87 Billion EUR | 0.0% |
| 2012 Q4 | 1.89 Billion EUR | 0.0% |
| 2011 Q4 | 1.77 Billion EUR | 0.0% |
| 2011 Q2 | 1.72 Billion EUR | 0.0% |
| 2011 FY | 1.77 Billion EUR | 0.8% |
| 2010 Q4 | 1.75 Billion EUR | 0.0% |
| 2010 FY | 1.75 Billion EUR | 4.83% |
| 2010 Q2 | 1.72 Billion EUR | 0.0% |
| 2009 Q4 | 1.67 Billion EUR | 0.0% |
| 2009 FY | 1.67 Billion EUR | -15.98% |
| 2008 FY | 1.99 Billion EUR | 4.72% |
| 2007 FY | 1.9 Billion EUR | -37.49% |
| 2006 FY | 3.04 Billion EUR | 197.75% |
| 2005 FY | 1.02 Billion EUR | 314.55% |
| 2004 FY | 247.01 Million EUR | -19.74% |
| 2003 FY | 307.78 Million EUR | 152.94% |
| 2002 FY | 121.68 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -13664.408% |
| Evofem Biosciences, Inc. | 8000.00 USD | -35974900.0% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -163843.858% |
| Mesoblast Limited | 100.29 Million USD | -2769.537% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -4907645.302% |
| Genus plc | 228.2 Million USD | -1161.174% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -431300.824% |
| ContraFect Corporation | 2.21 Million USD | -130126.244% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -205041.511% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -52936.222% |
| MultiCell Technologies, Inc. | 36.43 USD | -7900082249.712% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -5075.142% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -129190.207% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -234195.944% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | -1632.639% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -151495.918% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -1680680.237% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -52213252.685% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -10404.197% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -893688.82% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 74.393% |
| Halberd Corporation | 150 Thousand USD | -1918566.667% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -959233.333% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -1752587.19% |
| argenx SE | 15.35 Million USD | -18644.301% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -14068.964% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -64586973.609% |
| Genscript Biotech Corporation | 287.12 Million USD | -902.337% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -2278565.421% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1255073.557% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -518841.921% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -11375843.713% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -34725.75% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -1083341.565% |
| ONE Bio Corp. | 592.19 Thousand USD | -485886.106% |
| Reve Technologies, Inc. | 1064.00 USD | -270488621.805% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -1923516.774% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -1923516.774% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -1252887.71% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -2041034.752% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -3597400.0% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -36703.257% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -779742.243% |
| International Stem Cell Corporation | 445 Thousand USD | -646641.573% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -35212.883% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -629659.3% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -247789.75% |
| PureTech Health plc | 18.25 Million USD | -15669.863% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -1918566.667% |
| IXICO plc | 275 Thousand USD | -1046445.455% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -24209.486% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -10839.222% |
| CSL Limited | 11.23 Billion USD | 74.393% |
| Cellectis S.A. | 36.21 Million USD | -7847.829% |